

AMGEN INC  
Form 8-K  
July 26, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**July 26, 2013**

**AMGEN INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction)**

**000-12477**  
**(Commission)**

**95-3540776**

Edgar Filing: AMGEN INC - Form 8-K

of incorporation)

File Number)

(IRS Employer  
Identification No.)

One Amgen Center Drive

Thousand Oaks, California  
(Address of principal executive offices)

805-447-1000

91320-1799  
(Zip Code)

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

- (e) On July 26, 2013, the Compensation and Management Development Committee of the Board of Directors of Amgen Inc. (the Company ) approved a revision to the estimated value of post-retirement benefits to be provided to Mr. Kevin W. Sharer, the Company's former Chief Executive Officer and Chairman of the Board. As previously disclosed, the Company agreed to provide Mr. Sharer with secretarial, travel and technology support services for the five-year period commencing January 1, 2013 and ending December 31, 2017. As a result of modifications to the level of support to be provided, the estimated cost of the services is expected to be approximately \$100,000 per year during this five-year period.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: July 26, 2013

By: /s/ David J. Scott  
Name: David J. Scott  
Title: Senior Vice President, General Counsel  
  
and Secretary